Global Soliris Market, By Indication (Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), and Neuromyelitis Optica Spectrum Disorder (NMOSD)), By Age Group (Pediatric, Adult, and Geria

The global Soliris market is estimated to be valued at USD 2,080.2 million in 2025 and is expected to reach USD 982.6 million by 2032, exhibiting a compound annual growth rate (CAGR) of -10.2% from 2025 to 2032. The global Soliris market represents a notable segment within the rare disease therapeutics domain, known for pioneering complement inhibition therapy for life-threatening disorders such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica spectrum disorder (NMOSD). Soliris (eculizumab), a monoclonal antibody developed to inhibit complement protein C5, has historically transformed the standard of care in these indications. Its life-saving potential and targeted mechanism of action made it a benchmark in personalized medicine and rare disease management. However, despite its clinical significance, the Soliris market has reached a maturity phase and now faces mounting headwinds, signaling the beginning of a slow decline globally. The increasing availability of biosimilars, cost-containment policies, and a shift toward newer alternatives like Ultomiris are redefining the market outlook, shifting Soliris from a growth driver to a legacy therapy within the competitive pharmaceutical landscape.

Market Dynamics:

The current dynamics of the global Soliris market are shaped by a combination of diminishing growth drivers and intensifying market restraints. While past growth was driven by increased rare disease awareness, better diagnostic tools, and regulatory incentives for orphan drugs, the market is now witnessing stagnation and projected decline through 2032. The negative CAGR is primarily attributed to the expiration of key patents, leading to the global introduction of biosimilar competitors which offer similar therapeutic outcomes at significantly lower prices. This has eroded Soliris's pricing power and market share, especially in cost-sensitive and government-regulated markets.

Further, healthcare systems across Europe, Asia Pacific, and Latin America are tightening reimbursement policies and introducing pricing caps, making it increasingly difficult for Soliris to maintain formulary placement without steep discounts. Clinicians and payers are also shifting preference to newer-generation drugs like Ultomiris, which offer less frequent dosing and lower long-term costs. While opportunities still exist in untapped emerging markets and for off-label indications, these are unlikely to offset the overall revenue decline.

Key Features of the Study:

• This report provides in-depth analysis of the global Soliris market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Soliris market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Alexion Pharmaceuticals, Inc. (Part of AstraZeneca)
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Soliris market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Soliris market

• Indication Insights (Revenue, USD Mn, 2020 - 2032)
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Atypical Hemolytic Uremic Syndrome (aHUS)
• Generalized Myasthenia Gravis (gMG)
• Neuromyelitis Optica Spectrum Disorder (NMOSD)
• Age Group Insights (Revenue, USD Mn, 2020 - 2032)
• Pediatric
• Adult
• Geriatric
• End User Insights (Revenue, USD Mn, 2020 - 2032)
• Hospitals
• Specialty Clinics
• Infusion Centers
• Others (Academic & Research Institutions,etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Alexion Pharmaceuticals, Inc. (Part of AstraZeneca)